Sechel Therapeutics

Novel IP-protected technology to treat RNA viruses, including Covid-19. Customized for each RNA virus type, but will work even if seasonal or occasional mutations occur, for which vaccinations would be ineffective. If the proposed therapeutics developed and made available through the globe, this will not only help those who suffer from infections from respective RNA viruses, but will also limit the spread, and possibly ultimately eradicate them.

For some RNA viruses, vaccines and anti-viral small-molecule pharmaceutical drugs exist, but not for the others, such as Covid-19. Even for those for which vaccines and anti-viral small-molecule pharmaceutical drugs exist or will be developed in the future, those vaccines and anti-viral small-molecule pharmaceutical drugs may have limited or no protection for when the virus will mutate. Moreover, vaccinations and anti-viral small-molecule pharmaceutical drugs are not always sufficiently protective, especially for vulnerable populations with pre-existing conditions that place them at a higher risk group of dying or developing a disability.

Some viruses mutate seasonally, and even seasonal vaccinations do not always keep-up with mutations and many patients die every year even from seasonal influenza, or once-in-several-years from swine or avian influenza. Yet other viruses, mutate less frequently into more dangerous variants, for example, coronavirus mutated into deadly SARS-CoV in 2003, then again into deadly MERS‐CoV in 2012, and recently it has mutated yet again into another deadly version known as Covid-19 (a.k.a., SARS-CoV-2).

Therefore, there is a significant need for a new class of medicines that can directly target and effectively treat patients already infected with RNA viruses.

The novel IP-protected technology is intended to treat RNA viruses, including Covid-19, by blocking virus assembly within already infected cells. If new viral particles are unable to assemble, they will not infect other cells, thereby preventing its further spread through other cells and organs in the body. This is a biotechnology and the therapeutic product is a manufactured biologic.

The proposed therapeutics will not only help those who suffer from infections from respective RNA viruses, such as Covid-19, but will also limit the spread, and possibly ultimately eradicate them. This would provide enormous benefit to human health globally.

The proposed novel technology-based therapeutic solution directly addresses global pandemics caused by RNA viruses such as Covid-19.